In contrast to the clinically benign course of FHH, neonates with de-novo or paternally derived mutations in CaSR may present with neonatal severe primary hyperparathyroidism (NSHPT). The gene discussed is CASR; the disease is neonatal severe primary hyperparathyroidism.